Researchers have discovered a new potential drug target for the lethal wasting disease known as cancer cachexia. Their findings illustrate that even small groups of neurons in the brain can have an ...

EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) (“EOM”, the “Company”) an innovative clinical-stage biotechnology company focused on developing transformative treatments for chronic inflammatory ...

Pfizer researchers say they are developing a drug that might counteract a condition that leads to the death of cancer patients within a year of its diagnosis. Photo by Stephanie Lecocq/EPA-EFE Sept.

Dr. Charles Loprinzi shares the latest update to the management of cancer cachexia guideline. Dr. Loprinzi discusses the evidence that prompted the rapid update to the guideline and reviews the new ...

Cachexia, defined as a loss of body weight, fat, and muscle mass that occurs in patients with chronic diseases, including cancer, remains a notable clinical challenge. With limited viable treatment ...

Please provide your email address to receive an email when new articles are posted on . Patients with cancer cachexia assigned ponsegromab gained significantly more weight than those assigned placebo.

Cachexia is a metabolic disorder that causes uncontrolled weight loss and muscle wasting in chronic diseases and cancer. A new study by Helmholtz Munich, in collaboration with the Institute of ...

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the cancer cachexia therapeutics market and it is poised to grow by USD 568.85 million during 2019-2023, progressing at a CAGR of 6% during the ...